Acute Respiratory Distress Syndrome: Mechanisms, Diagnosis, Management, and Outcomes
Bottom Line
Acute respiratory distress syndrome (ARDS) is a life-threatening form of acute inflammatory lung injury and hypoxemic respiratory failure that affects approximately 10% of intensive care unit admissions globally, with hospital mortality rates of 35–46% depending on severity.
1. Definition and Clinical Significance
ARDS is an acute, diffuse, inflammatory lung injury characterized by increased permeability of the alveolar–capillary barrier, resulting in non-cardiogenic pulmonary edema, reduced lung compliance, and severe hypoxemia.
The clinical significance of ARDS is profound: it is a common, frequently underrecognized, and highly morbid syndrome in critically ill patients. The LUNG-SAFE study, a prospective cohort involving 459 ICUs across 50 countries, found that ARDS accounted for 10.4% of ICU admissions and 23.4% of mechanically ventilated patients.
2. Evolution of ARDS Definitions
2.1 The AECC Definition (1994)
The first consensus definition, developed by the American-European Consensus Conference (AECC), established four criteria: acute onset; PaO₂/FiO₂ ≤300 mm Hg for acute lung injury (ALI) and ≤200 mm Hg for ARDS; bilateral infiltrates on frontal chest radiograph; and pulmonary artery wedge pressure ≤18 mm Hg or no clinical evidence of left atrial hypertension.
While foundational, the AECC definition suffered from several limitations: the term "acute" was vaguely defined; inter-observer reliability in interpreting chest radiographs was poor; the PaO₂/FiO₂ criterion lacked standardization for positive end-expiratory pressure (PEEP); and the requirement for pulmonary artery catheterization was increasingly impractical as the use of pulmonary artery catheters declined.
2.2 The Berlin Definition (2012)
The Berlin Definition, published by an expert task force in JAMA in 2012, addressed these limitations through evidence-based refinement. Key changes included:
- Elimination of the term "ALI": ARDS was reclassified into three mutually exclusive severity categories rather than treated as the severe end of a spectrum.
- Explicit timing: "Acute" was defined as onset within one week of a known clinical insult or new/worsening respiratory symptoms.
- Oxygenation criteria with minimum PEEP: A minimum PEEP or CPAP of 5 cm H₂O is required to standardize the PaO₂/FiO₂ ratio measurement.
- Severity categories:
- Mild: 200 mm Hg < PaO₂/FiO₂ ≤ 300 mm Hg
- Moderate: 100 mm Hg < PaO₂/FiO₂ ≤ 200 mm Hg
- Severe: PaO₂/FiO₂ ≤ 100 mm Hg
- Radiographic clarification: Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules.
- Cardiac exclusion: Eliminated the specific pulmonary artery wedge pressure cutoff; requires that respiratory failure not be fully explained by cardiac failure or fluid overload.
The task force empirically validated the definition using patient-level meta-analysis of 4,188 patients, demonstrating superior predictive validity for mortality compared to the AECC definition (area under the receiver operating curve 0.577 vs. 0.536).
Limitations of the Berlin Definition include its reliance on arterial blood gas sampling (limiting applicability where ABG is unavailable), the requirement for invasive or noninvasive mechanical ventilation (excluding patients managed with high-flow nasal oxygen), and its inapplicability in resource-limited settings that lack PEEP-capable ventilators.
2.3 The Global Definition of ARDS (2023)
The 2023 Global Definition, endorsed by major critical-care societies, updates the Berlin framework to reflect modern clinical practice and global health equity:
- High-flow nasal oxygen (HFNO): Patients treated with HFNO at ≥30 L/min are now included, recognizing its widespread use since the FLORALI trial and the COVID-19 pandemic.
- SpO₂/FiO₂ criteria: Pulse oximetry-derived SpO₂/FiO₂ ≤315 (when SpO₂ ≤97%) is accepted as an alternative to PaO₂/FiO₂, broadening diagnostic access where ABG is unavailable.
- Lung ultrasound: Ultrasound identifying bilateral B-lines or consolidations by trained operators is now accepted as an imaging modality.
- Resource-limited settings: The requirement for PEEP, specific flow rates, or mechanical ventilation devices is removed.
The conceptual framework remains consistent: ARDS is an acute, diffuse, inflammatory lung injury precipitated by a known risk factor, resulting in pulmonary edema and impaired gas exchange not primarily explained by cardiogenic causes.
3. Pathophysiology
3.1 Alveolar–Capillary Barrier Injury
The alveolar–capillary membrane is the primary structural target in ARDS. Direct pulmonary insults (e.g., pneumonia, aspiration) primarily damage the alveolar epithelium, while indirect systemic insults (e.g., sepsis, pancreatitis) predominantly target the pulmonary vascular endothelium.
3.2 The Inflammatory Cascade
The inflammatory response in ARDS involves a coordinated but dysregulated interplay of cellular and molecular mediators:
- Alveolar macrophages are activated by the initial stimulus (pathogen-associated molecular patterns or damage-associated molecular patterns) and release pro-inflammatory cytokines including IL-1β, IL-6, IL-8, and TNF-α.
- Neutrophils are recruited via chemotaxis and undergo respiratory burst, releasing reactive oxygen species, proteases (including matrix metalloproteinases and neutrophil elastase), and pro-inflammatory mediators that propagate tissue injury.
- Neutrophil extracellular traps (NETs) — web-like chromatin structures released by dying neutrophils — promote platelet aggregation, microvascular thrombosis, and further alveolar–capillary barrier damage.
- Cytokine amplification drives a self-sustaining cascade that recruits additional inflammatory cells and activates the coagulation system.
3.3 Pulmonary Edema and Surfactant Dysfunction
The hallmark of ARDS is protein-rich, non-cardiogenic pulmonary edema. Unlike hydrostatic edema, ARDS edema results from increased vascular permeability rather than elevated capillary pressure.
Concurrently, epithelial injury depletes surfactant-producing type II alveolar epithelial cells, and the protein-rich edema fluid directly inactivates existing surfactant. The resulting increase in alveolar surface tension promotes end-expiratory alveolar collapse (atelectasis), worsening lung compliance and gas exchange.
3.4 Impaired Gas Exchange
Gas exchange impairment in ARDS is multifactorial. Ventilation–perfusion (V/Q) mismatch — blood flow to non-aerated or poorly aerated lung regions — is the dominant mechanism of hypoxemia. Increased dead-space ventilation (ventilation to non-perfused regions) contributes to impaired CO₂ elimination. Shunt physiology (perfusion of completely non-ventilated alveoli) produces hypoxemia refractory to supplemental oxygen.
3.5 Heterogeneous Lung Mechanics
A pathognomonic mechanical feature of ARDS is the marked heterogeneity of lung involvement. The lung is not uniformly diseased but rather comprises a patchwork of atelectatic/consolidated regions (dependent zones), edematous tissue, and relatively normal or overdistended regions (non-dependent zones). This creates the "baby lung" concept — the functional lung size may be dramatically reduced, often equivalent to the lung volume of a small child.
This mechanical heterogeneity predisposes to ventilator-induced lung injury (VILI) through:
- Volutrauma: Regional overdistension of aerated lung units.
- Atelectrauma: Cyclic recruitment and derecruitment of unstable alveoli.
- Biotrauma: Release of inflammatory mediators from mechanotransduction.
3.6 Temporal Phases
ARDS pathophysiology progresses through overlapping temporal phases:
- Exudative phase (days 1–7): Characterized by alveolar–capillary barrier disruption, protein-rich edema, neutrophil infiltration, and hyaline membrane formation.
- Fibroproliferative phase (days 7–21): Tissue remodeling with fibroblast proliferation, collagen deposition, and potential progression to fibrosis.
4. Direct Pulmonary versus Indirect Extrapulmonary Causes
ARDS is classically dichotomized by the pathway of injury:
Direct (Pulmonary) Causes
Direct injury results from an insult that reaches the lung epithelium via the airways:
| Cause | Frequency | Mechanism |
|---|---|---|
| Pneumonia (bacterial, viral, fungal) | Most common pulmonary cause | Direct epithelial infection and damage |
| Aspiration of gastric contents | Common | Chemical pneumonitis + bacterial superinfection |
| Inhalation injury | Less common | Toxic gas or smoke的直接 epithelial injury |
| Pulmonary contusion | Traumatic | Direct mechanical disruption of alveolar architecture |
| Near-drowning | Rare | Osmotic and chemical injury to epithelium |
Indirect (Extrapulmonary) Causes
Indirect injury results from a systemic inflammatory insult that reaches the lung via the bloodstream, primarily damaging the pulmonary endothelium:
| Cause | Frequency | Mechanism |
|---|---|---|
| Sepsis (non-pulmonary) | Most common overall cause | Systemic inflammation; endothelial activation and injury |
| Severe trauma with shock/multiple transfusions | Common | Ischemia–reperfusion; transfusion-related acute lung injury (TRALI) |
| Acute pancreatitis | Common | Systemic release of pancreatic enzymes and inflammatory mediators |
| Burns | Less common | Systemic inflammatory response syndrome |
| Drug overdose/toxicity | Less common | Direct or immune-mediated injury |
| Cardiopulmonary bypass | Rare | Systemic inflammation from bypass circuit |
The distinction has pathophysiological relevance: direct injury produces more prominent alveolar epithelial damage, alveolar collapse, and thicker hyaline membranes, while indirect injury is associated with more diffuse endothelial injury and systemic inflammation.
5. Epidemiology and Risk Factors
5.1 Incidence
The LUNG-SAFE study remains the largest epidemiological investigation, reporting that ARDS constitutes 10.4% of ICU admissions and 23.4% of mechanically ventilated patients.
5.2 Risk Factors
Established risk factors include:
- Demographics: Male sex; age >65 years (most patients are in their sixth or seventh decade)
- Comorbidities: Diabetes mellitus, obesity, chronic obstructive pulmonary disease, chronic heart failure, chronic liver disease, alcohol use disorder
- Acute risk factors: Sepsis (pulmonary or non-pulmonary), severe trauma, aspiration, pancreatitis, multiple transfusions, burn injury, drug overdose
- Genetic factors: Polymorphisms in genes encoding angiotensin-converting enzyme, surfactant proteins, and inflammatory cytokines have been associated with differential susceptibility, though none are clinically actionable
In low- and middle-income countries, infectious pathogens such as Plasmodium species, dengue virus, and Leptospira contribute additional risk, and limited diagnostic resources likely lead to substantial underdetection.
5.3 Mortality
Pre-pandemic ARDS mortality from the LUNG-SAFE study was 34.9% (mild), 40.3% (moderate), and 46.1% (severe), with an overall mortality of approximately 40%.
6. Clinical Presentation and Diagnostic Workup
6.1 Clinical Presentation
Patients typically present with acute-onset dyspnea and hypoxemia that worsen progressively within 6–72 hours of an inciting event. Physical examination reveals tachypnea, increased work of breathing (accessory muscle use, intercostal retractions), and diffuse crackles (rales) on auscultation, frequently bibasilar. Tachycardia, altered mental status from hypoxemia, and central or peripheral cyanosis may be present.
6.2 Diagnostic Workup
The diagnosis of ARDS is based on the Berlin/Global Definition criteria, requiring:
Imaging:
- Chest radiography or CT: Bilateral opacities not fully explained by effusions, atelectasis, or nodules.
- Lung ultrasound (per Global Definition): Bilateral B-lines or consolidations in a pattern consistent with non-cardiogenic pulmonary edema.
- CT may further characterize disease distribution and identify complications (pneumothorax, pleural effusion, barotrauma).
Oxygenation assessment:
- PaO₂/FiO₂ ratio (requiring arterial blood gas) with minimum PEEP/CPAP of 5 cm H₂O.
- SpO₂/FiO₂ ratio ≤315 (when SpO₂ ≤97%) as alternative per Global Definition.
Cardiac evaluation to exclude cardiogenic edema:
- Echocardiography (preferred noninvasive method) to assess left ventricular systolic and diastolic function.
- B-type natriuretic peptide (BNP) or N-terminal proBNP — though levels overlap substantially between ARDS and cardiogenic edema, particularly when right heart strain or sepsis elevates BNP in ARDS.
- Pulmonary artery catheterization is generally not recommended for routine diagnosis.
Laboratory evaluation:
- Complete blood count with differential, comprehensive metabolic panel, coagulation profile, lactate, troponin, blood cultures, and respiratory viral/bacterial testing.
- Bronchoscopy with bronchoalveolar lavage may be indicated when infection is suspected and noninvasive sampling is negative.
7. Differential Diagnosis
Differentiating ARDS from cardiogenic pulmonary edema is the most critical diagnostic challenge, and the two conditions may coexist ("mixed edema"), particularly in elderly patients with heart disease and sepsis. Key distinguishing features:
| Feature | ARDS | Cardiogenic Pulmonary Edema |
|---|---|---|
| Onset | Within 7 days of insult | Often acute with cardiac event |
| Risk factors | Sepsis, pneumonia, aspiration, trauma, pancreatitis | Hypertension, coronary disease, valvular disease, cardiomyopathy |
| Imaging | Patchy, peripheral, asymmetrical opacities | Central/"bat wing" distribution, Kerley B lines, pleural effusions |
| Chest ultrasound | Spared areas, subpleural consolidation, pleural line abnormalities | Homogeneous B-lines |
| BNP/NT-proBNP | Variable (may be elevated due to right heart strain) | Markedly elevated |
| Echocardiography | Normal LV function (usually) | LV systolic or diastolic dysfunction |
| Response to diuretics | Poor | Often rapid improvement |
| Pulmonary artery occlusion pressure | ≤18 mm Hg (if measured) | >18 mm Hg |
Other important differential diagnoses include bilateral pneumonia, diffuse alveolar hemorrhage, acute interstitial pneumonia, acute eosinophilic pneumonia, cryptogenic organizing pneumonia, exacerbation of interstitial lung disease, pulmonary vasculitis, and disseminated malignancy.
8. Evidence-Based Management
The management of ARDS is organized around (1) lung-protective mechanical ventilation, (2) adjunctive therapies targeting specific pathophysiological derangements, (3) treatment of the underlying cause, and (4) rescue therapies for refractory cases.
8.1 Lung-Protective Mechanical Ventilation
Low tidal volume ventilation is the single most important intervention. The landmark ARMA trial (ARDS Network, 2000) randomized 861 patients to 6 mL/kg versus 12 mL/kg tidal volume (predicted body weight), with plateau pressure ≤30 cm H₂O in the low-volume group. The trial was stopped early when 28-day mortality was 31.0% in the low-volume group versus 39.8% in the traditional group (P = 0.007), and ventilator-free days were significantly increased.
Driving pressure (ΔP = tidal volume / respiratory system compliance) has emerged as a critical prognostic marker. A secondary analysis of multiple ARDS Network trials demonstrated that ΔP was the ventilation variable most strongly associated with survival: reductions in ΔP mediated 75% of the treatment effect in tidal volume trials and 45% in PEEP trials. A 1-SD increase in ΔP (approximately 7 cm H₂O) was associated with increased mortality even among patients receiving "protective" tidal volumes and plateau pressures.
8.2 Positive End-Expiratory Pressure (PEEP)
The optimal PEEP strategy remains controversial. Higher PEEP can recruit collapsed lung units, improve oxygenation, and reduce atelectrauma, but may also cause overdistension and hemodynamic compromise.
Key trials:
- The EXPRESS trial compared high PEEP (titrated to plateau pressure 28–30 cm H₂O) versus low PEEP and found no difference in hospital mortality, though the high-PEEP group had improved oxygenation and more organ-failure–free days.
- The ART trial (2017) tested a lung recruitment maneuver (prolonged, high-pressure inflation) plus PEEP titration against a conventional low-PEEP strategy. The experimental strategy significantly increased 28-day mortality (55.3% vs. 49.3%; HR 1.20) and 6-month mortality, with more barotrauma (5.6% vs. 1.6%).
Current guidelines:
- Conditional recommendation for higher PEEP without lung recruitment maneuvers in moderate-to-severe ARDS (low-to-moderate certainty of evidence).
- Strong recommendation against prolonged lung recruitment maneuvers (airway pressure >35 cm H₂O for >60 seconds) in moderate-to-severe ARDS due to adverse hemodynamic effects.
Network meta-analysis suggests that higher PEEP without recruitment maneuvers is associated with lower mortality than both lower PEEP and higher PEEP with prolonged recruitment maneuvers.
8.3 Prone Positioning
The PROSEVA trial (2013) provided definitive evidence for prone positioning in severe ARDS. In this multicenter trial, patients with PaO₂/FiO₂ <150 mm Hg who were placed prone for ≥16 hours daily had dramatically lower mortality: 28-day mortality 16.0% in the prone group versus 32.8% in the supine group (P < 0.001), with a hazard ratio for death of 0.39 (95% CI 0.25–0.63).
Guidelines make a strong recommendation for prone positioning for >12 hours daily in patients with severe ARDS (PaO₂/FiO₂ <150 mm Hg).
8.4 Fluid Management
The FACTT trial (ARDS Network, 2006) randomized 1,000 patients to a conservative versus liberal fluid management strategy for seven days. While 60-day mortality did not differ between groups, the conservative strategy significantly improved lung function, shortened duration of mechanical ventilation, and reduced ICU length of stay without increasing non-pulmonary organ failure.
Current practice favors a conservative fluid strategy (targeting net even to negative fluid balance) once shock has resolved, guided by dynamic measures of fluid responsiveness rather than static pressure targets. Pulmonary artery catheterization is not recommended for routine management, as FACTT found no benefit over central venous catheter guidance and more complications with PAC use.
8.5 Neuromuscular Blockade (NMB)
The role of neuromuscular blockade has been one of the most contested areas in ARDS management:
ACURASYS trial (2010): Early, 48-hour infusion of cisatracurium in patients with severe ARDS (PaO₂/FiO₂ <150) was associated with lower adjusted 90-day mortality (HR 0.68; 95% CI 0.48–0.98; P = 0.04) and more ventilator-free days.
ROSE trial (2019): In a contemporary setting with protocolized lung-protective ventilation and lighter sedation targets, early cisatracurium showed no benefit — 90-day mortality was 42.5% in the intervention group versus 42.8% in controls (P = 0.93), and the trial was stopped early for futility. The NMB group had more serious cardiovascular adverse events.
Current guidelines provide a conditional recommendation for NMB use in patients with early (<48 hours) severe ARDS (PaO₂/FiO₂ ≤100 mm Hg), emphasizing that NMB should be used only after optimizing sedation and mechanical ventilation, for a limited duration (≤48 hours when possible).
8.6 Corticosteroids
The DEXA-ARDS trial (2020) randomized patients with moderate-to-severe ARDS to dexamethasone (20 mg daily for 5 days, then 10 mg for 5 days) or placebo. Dexamethasone significantly increased ventilator-free days (12.3 vs. 7.5) and reduced 60-day mortality (21% vs. 36%).
Pooled analysis of 19 RCTs by the 2023 ATS guideline update indicates that corticosteroids likely decrease mortality and reduce duration of mechanical ventilation and hospital stay, though with increased risk of serious hyperglycemia.
8.7 Extracorporeal Membrane Oxygenation (ECMO)
The EOLIA trial (2018) randomized patients with very severe ARDS (PaO₂/FiO₂ <50 for >3 hours, or <80 for >6 hours, or pH <7.25 with PaCO₂ ≥60) to immediate venovenous ECMO versus continued conventional management (with ECMO permitted as rescue for refractory hypoxemia). At 60 days, 35% of the ECMO group died versus 46% of controls (relative risk 0.76; 95% CI 0.55–1.04; P = 0.09) — a 9% absolute risk reduction that did not reach statistical significance. However, 28% of control patients crossed over to ECMO as rescue, complicating interpretation.
The 2023 ATS guideline provides a conditional recommendation for VV-ECMO in selected patients with severe ARDS (low certainty of evidence), noting that it may decrease mortality and increase organ-failure–free days, but increases hemorrhage risk. ECMO is recommended for patients with severe hypoxemia or hypercapnia despite optimal conventional management, preferably within the first 7 days of ARDS, at experienced centers.
8.8 Rescue Therapies for Refractory Hypoxemia
Inhaled pulmonary vasodilators (inhaled nitric oxide, inhaled epoprostenol) improve oxygenation by selectively dilating vessels in ventilated lung regions, reducing shunt fraction. However, meta-analyses demonstrate no improvement in survival, and inhaled nitric oxide is associated with increased risk of renal replacement therapy. Current guidelines recommend against routine use; these agents are reserved as a temporary bridge to ECMO.
8.9 Treatment of Underlying Cause
Definitive management requires identification and treatment of the precipitating condition: appropriate antimicrobial therapy for sepsis/pneumonia, source control for intra-abdominal infection, supportive care for pancreatitis, and management of shock. Time-sensitive antibiotic administration in septic patients directly influences outcomes.
9. ARDS Subphenotypes and Precision Medicine
Latent class analysis of clinical and biomarker data has consistently identified two biological subphenotypes:
- Hyperinflammatory phenotype: Higher plasma IL-6, IL-8, lower serum bicarbonate, higher vasopressor requirements; associated with higher mortality.
- Hypoinflammatory phenotype: Lower inflammatory cytokines, better metabolic profile; lower mortality.
Post-hoc analyses of RCTs suggest differential treatment responses: the hyperinflammatory phenotype may derive greater benefit from higher PEEP, conservative fluid management, and simvastatin, while the hypoinflammatory phenotype does not.
Researchers have developed parsimonious classifiers using as few as 3–4 variables (e.g., IL-8, bicarbonate, vasopressor use) to identify subphenotypes at the bedside,
10. Outcomes and Long-Term Sequelae
10.1 In-Hospital Mortality
Pre-pandemic mortality rates from LUNG-SAFE: 34.9% (mild), 40.3% (moderate), 46.1% (severe).
10.2 Pulmonary Recovery
Most survivors return to normal or near-normal pulmonary function within 6–12 months, though a mild restrictive defect and reduced diffusion capacity (DLCO) commonly persist.
10.3 Physical Recovery
Persistent functional limitations are common. At 5-year follow-up, ARDS survivors demonstrated median 6-minute walk distances approximately 76% of predicted, with ICU-acquired weakness as a major determinant.
10.4 Cognitive Impairment
Cognitive deficits are present in 70–100% of survivors at hospital discharge, 46–80% at 1 year, and approximately 20% at 5 years.
10.5 Psychological Sequelae
Prolonged psychiatric symptoms are highly prevalent. A 5-year longitudinal study found that 52% of survivors experienced continuous or recurring symptoms: anxiety (38%), depression (32%), and post-traumatic stress disorder (23%).
10.6 Quality of Life
Health-related quality of life (measured by SF-36) remains significantly below population norms at 5 years, particularly in physical domains. These deficits are more strongly linked to muscle weakness and systemic sequelae than to residual pulmonary dysfunction.
11. Health Inequities in ARDS
Growing evidence documents substantial disparities in ARDS outcomes:
Racial and ethnic disparities: Black patients have higher ARDS incidence than White patients (OR 1.16 in trauma-associated ARDS).
Mechanisms of inequity:
- Undetected hypoxemia: Pulse oximetry is less accurate in patients with darker skin tones, leading to occult hypoxemia and delayed recognition of deterioration.
- Differential sedation: Hispanic patients with ARDS have approximately 5 times the odds of receiving deep sedation compared to non-Hispanic White patients, which is associated with worse outcomes.
- Structural factors: Socioeconomic barriers to healthcare access, environmental exposures, multigenerational housing, occupational risk, insurance status, and systemic underinvestment in public health — particularly in the Southern United States — contribute to higher exposure and worse outcomes.
- Hospital factors: Admission to "safety-net" hospitals is associated with increased mortality and longer lengths of stay. Underinsured patients are more likely to receive non-lung-protective ventilation.
12. COVID-19-Associated ARDS
The pandemic provided both a natural experiment and a challenge to conventional ARDS management.
12.1 Distinctive Pathobiology
COVID-19-associated ARDS (CARDS) shares core features with classic ARDS but exhibits distinctive vascular pathology:
- Severe endothelialitis: Direct infection of endothelial cells by SARS-CoV-2, with upregulation of adhesion molecules (VCAM1, ICAM1) and downregulation of VE-cadherin.
- Immunothrombosis: Extensive micro- and macro-thrombi, with microthrombi up to 9 times more frequent than in influenza ARDS. NET-mediated platelet activation and suppressed fibrinolysis (elevated plasminogen activator inhibitor-1) contribute.
- L-type and H-type phenotypes: Early CARDS often presents with profound hypoxemia but near-normal respiratory compliance ("L-type"), challenging conventional assumptions that severe hypoxemia implies recruitable, poorly compliant lungs. Later progression to "H-type" with decreased compliance and higher recruitability may occur.
12.2 Management Lessons
- Standard lung-protective ventilation (low tidal volume, driving pressure limitation) remains foundational.
- High PEEP may be deleterious in the L-type phenotype due to overdistension of relatively normal lung regions and adverse hemodynamic effects. PEEP should be individualized based on recruitability assessment.
- Corticosteroids (dexamethasone) demonstrated clear mortality benefit in the RECOVERY trial and are standard of care.
- Anticoagulation: Despite extensive thrombosis, full therapeutic anticoagulation was not superior to prophylactic anticoagulation in randomized trials, emphasizing the inflammatory driver of thrombotic risk.
- The pandemic underscored the need for phenotype-based, personalized ventilatory strategies rather than a "one-size-fits-all" approach.
13. Limitations and Evidence Gaps
Definitional limitations: The 2023 Global Definition improves inclusivity but the SpO₂/FiO₂ criterion loses accuracy at high saturations and in patients with darker skin pigmentation. The clinical and prognostic equivalence of cases identified by the resource-limited definition versus the full definition requires further validation.
Pathophysiological gaps: While hyperinflammatory and hypoinflammatory subphenotypes are reproducible in research cohorts, there is no validated point-of-care platform for real-time phenotype identification. The transition from endothelial injury to fibroproliferation is incompletely understood, and no therapies directly target this transition.
Management evidence gaps:
- Driving pressure–guided ventilation has not been prospectively validated as a ventilation target in a randomized trial.
- ECMO: The EOLIA trial did not reach statistical significance; the role of ECMO versus continued conventional therapy is debated, particularly given the high crossover rate. Ongoing trials may clarify benefit in specific subgroups.
- Neuromuscular blockade: The discordance between ACURASYS and ROSE highlights uncertainty about the appropriate comparator (deep vs. light sedation), optimal agent, and duration. The role of NMB in specific phenotypes is unknown.
- Fluid management: The optimal timing, monitoring modality (dynamic vs. static indices), and role of albumin remain undefined.
- Corticosteroids: The optimal agent, dose, timing, and duration — and whether benefit is uniform across subphenotypes — remain uncertain.
Long-term outcome gaps: Mechanisms linking critical illness to persistent cognitive impairment are poorly understood. Effective post-ICU rehabilitation interventions (physical, cognitive, psychological) are lacking, and most survivors do not receive structured follow-up.
Health equity gaps: The mechanisms driving disparities in ARDS care and outcomes are incompletely characterized, and no interventions have been prospectively tested to reduce them.
14. TLDR
ARDS is an acute, diffuse, inflammatory lung injury causing non-cardiogenic pulmonary edema and hypoxemic respiratory failure. The diagnostic framework evolved from the 1994 AECC criteria through the 2012 Berlin Definition (mild/moderate/severe categories based on PaO₂/FiO₂) to the 2023 Global Definition, which now includes HFNO, SpO₂/FiO₂ criteria, lung ultrasound, and a resource-limited adaptation. Pathophysiology centers on alveolar–capillary barrier disruption, neutrophil-driven inflammation, surfactant inactivation, heterogeneous lung mechanics, and VILI risk. Direct causes (pneumonia, aspiration) damage the epithelium; indirect causes (sepsis, pancreatitis, trauma) damage the endothelium. Management is anchored by low tidal volume ventilation (6 mL/kg) and plateau pressure ≤30 cm H₂O, with adjunctive therapies including prone positioning (strong recommendation for severe ARDS), conservative fluid strategies once shock resolves, and conditional use of corticosteroids, higher PEEP, neuromuscular blockade (early severe ARDS only, ≤48 hours), and VV-ECMO (selected severe cases). Major trials (ARMA, PROSEVA, FACTT, ACURASYS, ROSE, DEXA-ARDS, EOLIA, ART) have defined and refined the evidence base. Mortality is 35–46%, and survivors face persistent physical, cognitive, and psychological impairments lasting years. COVID-19 ARDS revealed distinctive vascular immunothrombosis and highlighted the need for phenotype-specific care. Health inequities by race, ethnicity, and socioeconomic status are substantial and multifactorial. Major research gaps include real-time subphenotype identification, prospective validation of driving pressure targets, and effective post-ICU rehabilitation interventions.
Companion Files
No companion files accompany this report.
Create from ARDS: mechanisms, diagnosis, treatment, outcomes
Created from this
Reports
A New Global Definition of Acute Respiratory Distress Syndrome
doi.org
American Thoracic Society | Experts Propose New Global Definition of…
site.thoracic.org
A New Global Definition of Acute Respiratory... : American Journal of Respiratory and Critical Care Medicine
ovid.com
A New Global Definition of Acute Respiratory Distress Syndrome. - Abstract - Europe PMC
europepmc.org
CLEP-28800-acute-respiratory-distress-syndrome--ards---epidemiology-and
ncbi.nlm.nih.gov
Acute respiratory distress syndrome: the Berlin Definition - PubMed
pubmed.ncbi.nlm.nih.gov
Improvements in the Definition of Acute Respiratory Distress Syndrome
doi.org
Acute Respiratory Distress Syndrome: The Berlin Definition | Critical Care Medicine | JAMA | JAMA Network
jamanetwork.com
Current Opinion in Critical Care
journals.lww.com
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material
doi.org
Critical Care Medicine
journals.lww.com
Surviving Sepsis Campaign Guidelines 2021 | SCCM
sccm.org
Checking your browser - reCAPTCHA
pmc.ncbi.nlm.nih.gov
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 | Intensive Care Medicine | Springer Nature Link
link.springer.com
Acute respiratory distress syndrome | The BMJ
bmj.com
Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome
mdpi-res.com
Acute Respiratory Distress Syndrome: Pathophysiological Insights, Subphenotypes, and Clinical Implications—A Comprehensive Review
mdpi.com
A narrative review on the future of ARDS: evolving definitions, pathophysiology, and tailored management | Critical Care | Springer Nature Link
link.springer.com
Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome | New England Journal of Medicine
nejm.org
Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome | JournalJams
journaljams.org
Prone Positioning in Severe Acute Respiratory Distress Syndrome
doi.org
‘To prone or not to prone’ in severe ARDS: questions answered, but others remain
ccforum.biomedcentral.com
Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults - UpToDate
uptodate.com
Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms | Critical Care | Springer Nature Link
link.springer.com
Definition and epidemiology of acute respiratory distress syndrome
pmc.ncbi.nlm.nih.gov
Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome | New England Journal of Medicine
nejm.org
Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome - PMC
pmc.ncbi.nlm.nih.gov
ROSE
criticalcarereviews.com
Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome
nejm.org
dbGaP Study
ncbi.nlm.nih.gov
BioLINCC: Acute Respiratory Distress Network (ARDSNet) Study 05 Fluid and Catheter Treatment Trial (FACTT)
biolincc.nhlbi.nih.gov
Comparison of Two Fluid-Management Strategies in Acute Lung Injury | New England Journal of Medicine
nejm.org
NIH/ARDS Network Fluid Management Trial (The FACTT Study)
medscape.org
Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome
pubmed.ncbi.nlm.nih.gov
Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. - Abstract - Europe PMC
europepmc.org
Use of ECMO in ARDS: does the EOLIA trial really help?
doi.org
ECMO in Severe ARDS: Trial Halted for Futility, Lessons Debated
medscape.com
COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review)
doi.org
Checking your browser - reCAPTCHA
pmc.ncbi.nlm.nih.gov
COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment - A narrative review
pubmed.ncbi.nlm.nih.gov
Ventilatory Management of Patients with Acute Respiratory Distress Syndrome Due to SARS-CoV-2
mdpi.com
Disparities among patients with respiratory failure
doi.org
Disparities among Patients with Respiratory Failure - PMC
pmc.ncbi.nlm.nih.gov
A37-21 Racial and Ethnic Disparities in Acute Respiratory Distress Syndrome Related Mortality During the COVID-19 Pandemic: A U.S. Population-based Study From 2018 to 2023
doi.org
Biology meets physiology in ARDS precision medicine - The Lancet Respiratory Medicine
thelancet.com
Advancing Precision Medicine for the Diagnosis and Treatment of Acute Respiratory Distress Syndrome
pmc.ncbi.nlm.nih.gov
Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research
ddd.uab.cat
Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials - The Lancet Respiratory Medicine
thelancet.com
A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema
pubmed.ncbi.nlm.nih.gov
Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study
pmc.ncbi.nlm.nih.gov
Diagnostic utility of C-reactive Protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study
respiratory-research.biomedcentral.com
The Role of Chest Ultrasound Combined with Plasma Brain Natriuretic Peptide in The Differentiation between Cardiogenic and Noncardiogenic Pulmonary Edema
doi.org
Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries
doi.org
Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries
pureadmin.qub.ac.uk
Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries | Critical Care Medicine | JAMA | JAMA Network
jamanetwork-com.libproxy.ajou.ac.kr
Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries | Critical Care Medicine | JAMA | JAMA Network
jamanetwork.com
PulmCrit - Steroid for ARDS? The DEXA-ARDS trial
emcrit.org
DEXA-ARDS – The Bottom Line
thebottomline.org.uk
Dexamethasone in Hospitalized Patients with Covid-19 | New England Journal of Medicine
nejm.org
Functional disability 5 years after acute respiratory distress syndrome
pubmed.ncbi.nlm.nih.gov
Physical and psychological impairment in survivors of acute respiratory distress syndrome: a systematic review and meta-analysis
iris.hunimed.eu
Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers
link.springer.com
Psychiatric symptoms after acute respiratory distress syndrome: a 5-year longitudinal study - PubMed
pubmed.ncbi.nlm.nih.gov
An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome - PubMed
pubmed.ncbi.nlm.nih.gov
An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome
thoracic.org
An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline
doi.org
An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine
atsjournals.org
Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes
doi.org
Acute respiratory distress syndrome
bmj.com
Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes - The Lancet
thelancet.com
Acute Respiratory Distress Syndrome - StatPearls - NCBI Bookshelf
ncbi.nlm.nih.gov
Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. - Abstract - Europe PMC
europepmc.org
Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial | Trials | Springer Nature Link
link.springer.com
Checking your browser - reCAPTCHA
pmc.ncbi.nlm.nih.gov
Driving Pressure and Survival in the Acute Respiratory Distress Syndrome | New England Journal of Medicine
nejm.org
Inhaled nitric oxide for acute respiratory distress syndrome in adults: a systematic review and meta-analysis | Journal of Intensive Care | Springer Nature Link
link.springer.com
Inhaled nitric oxide for acute respiratory distress syndrome in adults: a systematic review and meta-analysis - PMC
pmc.ncbi.nlm.nih.gov
Checking your browser - reCAPTCHA
pmc.ncbi.nlm.nih.gov
Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS - PubMed
pubmed.ncbi.nlm.nih.gov
The Current State of Pediatric Acute Respiratory Distress Syndrome - PMC
pmc.ncbi.nlm.nih.gov
Pediatric Acute Respiratory Distress Syndrome Updates in the Light of the PALICC-2 Guidelines - PMC
pmc.ncbi.nlm.nih.gov
Definition, Incidence, and Epidemiology of Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference - Penn State
pure.psu.edu
COVID-19-Related ARDS: Key Mechanistic Features and Treatments
mdpi.com
Endothelial cell infection and dysfunction, immune activation in severe COVID-19
thno.org
Endothelialitis, Microischemia, and Intussusceptive Angiogenesis in COVID-19
perspectivesinmedicine.cshlp.org
Frontiers | Immunothrombosis in Acute Respiratory Dysfunction of COVID-19
frontiersin.org
For Patients with Severe Lung Injury, Less Is More
nih.gov
High levels of PEEP may improve survival in acute respiratory distress syndrome: A meta-analysis
sciencedirect.com
Effects of higher PEEP and recruitment manoeuvres on mortality in patients with ARDS: a systematic review, meta-analysis, meta-regression and trial sequential analysis of randomized controlled trials
doi.org
Association of Positive End-Expiratory Pressure and Lung Recruitment Selection Strategies with Mortality in Acute Respiratory Distress Syndrome: A Systematic Review and Network Meta-analysis
doi.org
Higher PEEP for acute respiratory distress syndrome: a Bayesian meta-analysis of randomised clinical trials
doi.org
An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline - PMC
pmc.ncbi.nlm.nih.gov
An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline
pubmed.ncbi.nlm.nih.gov
Executive Summary: Society of Critical Care Medicine Guidelines for the Administration of Neuromuscular Blockade in Adults With Acute Respiratory Distress Syndrome
doi.org
Trends and racial disparities in mortality related to acute respiratory distress syndrome - PMC
pmc.ncbi.nlm.nih.gov
Trends and racial disparities in mortality related to acute respiratory distress syndrome
doi.org
Ethnic Disparities in Deep Sedation of Patients with Acute Respiratory Distress Syndrome in the United States: Secondary Analysis of a Multicenter Randomized Trial
doi.org